Axa’s Elevance Health ELV Stock Holding History

Axa’s Portfolio ELV Stock Details ELV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-95,281	Closed	-$37.1M	–	387
2025 Q2	$37.1M	Buy	95,281 +43,434	+84%	+$17.5M	0.11%	176
2025 Q1	$22.6M	Sell	51,847 -32,515	-39%	-$13.1M	0.07%	251
2024 Q4	$31.1M	Sell	84,362 -170,546	-67%	-$71.4M	0.09%	204
2024 Q3	$133M	Buy	254,908 +17,643	+7%	+$9.43M	0.39%	54
2024 Q2	$129M	Buy	237,265 +141,250	+147%	+$74.7M	0.38%	52
2024 Q1	$49.8M	Sell	96,015 -95,828	-50%	-$47.7M	0.15%	141
2023 Q4	$90.5M	Sell	191,843 -4,201	-2%	-$1.94M	0.29%	83
2023 Q3	$85.4M	Sell	196,044 -41,871	-18%	-$19M	0.3%	79
2023 Q2	$106M	Sell	237,915 -42,628	-15%	-$19.7M	0.35%	66
2023 Q1	$129M	Sell	280,543 -12,746	-4%	-$6.07M	0.44%	45
2022 Q4	$150M	Buy	293,289 +66,650	+29%	+$33.8M	0.54%	31
2022 Q3	$103M	Sell	226,639 -2,645	-1%	-$1.27M	0.41%	52
2022 Q2	$111M	Buy	229,284 +1,963	+0.9%	+$971K	0.41%	55
2022 Q1	$112M	Sell	227,321 -5,148	-2%	-$2.35M	0.32%	77
2021 Q4	$108M	Sell	232,469 -4,614	-2%	-$1.94M	0.28%	89
2021 Q3	$88.4M	Sell	237,083 -3,041	-1%	-$1.16M	0.25%	93
2021 Q2	$91.7M	Buy	240,124 +11,125	+5%	+$4.25M	0.26%	90
2021 Q1	$82.2M	Buy	228,999 +16,259	+8%	+$5.23M	0.25%	94
2020 Q4	$68.3M	Sell	212,740 -55,414	-21%	-$17M	0.21%	119
2020 Q3	$72M	Sell	268,154 -12,060	-4%	-$3.24M	0.26%	87
2020 Q2	$73.7M	Buy	280,214 +40,420	+17%	+$10.8M	0.29%	84
2020 Q1	$54.4M	Buy	239,794 +37,062	+18%	+$10.1M	0.27%	90
2019 Q4	$61.2M	Sell	202,732 -5,368	-3%	-$1.48M	0.25%	99
2019 Q3	$50M	Sell	208,100 -13,341	-6%	-$3.66M	0.2%	132
2019 Q2	$62.5M	Sell	221,441 -5,545	-2%	-$1.51M	0.24%	113
2019 Q1	$65.1M	Sell	226,986 -98,948	-30%	-$28.6M	0.25%	111
2018 Q4	$85.6M	Buy	325,934 +97,208	+42%	+$26.7M	0.37%	64
2018 Q3	$62.7M	Buy	228,726 +24,585	+12%	+$6.38M	0.23%	123
2018 Q2	$48.6M	Buy	204,141 +1,615	+0.8%	+$374K	0.19%	148
2018 Q1	$44.5M	Sell	202,526 -42,058	-17%	-$9.88M	0.18%	156
2017 Q4	$55M	Buy	244,584 +16,196	+7%	+$3.45M	0.22%	135
2017 Q3	$43.4M	Buy	228,388 +24,916	+12%	+$4.74M	0.19%	162
2017 Q2	$38.3M	Sell	203,472 -2,890	-1%	-$519K	0.17%	170
2017 Q1	$34.1M	Buy	206,362 +1,538	+0.8%	+$245K	0.15%	190
2016 Q4	$29.4M	Buy	204,824 +21,467	+12%	+$2.87M	0.14%	199
2016 Q3	$23M	Buy	183,357 +10,710	+6%	+$1.38M	0.1%	238
2016 Q2	$22.7M	Sell	172,647 -7,242	-4%	-$991K	0.1%	245
2016 Q1	$25M	Sell	179,889 -22,039	-11%	-$2.95M	0.11%	226
2015 Q4	$28.2M	Buy	201,928 +9,986	+5%	+$1.38M	0.12%	216
2015 Q3	$26.9M	Sell	191,942 -18,881	-9%	-$2.84M	0.11%	213
2015 Q2	$34.6M	Sell	210,823 -49,853	-19%	-$7.97M	0.14%	186
2015 Q1	$40.3M	Buy	260,676 +74,781	+40%	+$10.6M	0.17%	164
2014 Q4	$23.4M	Buy	185,895 +2,904	+2%	+$359K	0.09%	237
2014 Q3	$21.9M	Buy	182,991 +17,449	+11%	+$2M	0.09%	243
2014 Q2	$17.8M	Sell	165,542 -3,173	-2%	-$327K	0.07%	288
2014 Q1	$16.8M	Sell	168,715 -6,561	-4%	-$593K	0.07%	283
2013 Q4	$16.2M	Buy	175,276 +16,442	+10%	+$1.46M	0.07%	284
2013 Q3	$13.3M	Buy	158,834 +38,429	+32%	+$3.29M	0.07%	305
2013 Q2	$9.85M	Buy	+120,405	New	+$9.01M	0.05%	335

Other funds holding ELV

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Sanders Capital West Palm Beach, Florida $83.9B AUM 37.89% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

First Eagle Investment Management New York $59B AUM 32.99% 1-Year Est. Return

Harris Associates Chicago, Illinois $75B AUM 11.27% 1-Year Est. Return

Axa's ELV Position: Q3 2025 in Review

Axa sold out of Elevance Health (ELV) in Q3 2025, closing a stake of 95,281 shares — an estimated $37.1M sold.

Axa first reported a position in ELV in Q2 2013 and held it in 49 quarters. The position peaked at $150M in Q4 2022. 1,511 funds tracked by Wall St. Rank hold ELV as of Q3 2025.

Axa reported no remaining Elevance Health position as of Q3 2025 after selling out during the quarter.
Axa sold 95,281 Elevance Health shares in Q3 2025, an estimated $37.1M.
Axa first reported a position in Elevance Health in Q2 2013 and held it in 49 quarters.
Axa's Elevance Health position peaked at $150M in Q4 2022.
1,511 funds tracked by Wall St. Rank held Elevance Health as of Q3 2025.

Based on Axa's 13F filing for Q3 2025, filed 14 Nov 2025.